GlassScriptPhysician profile
Rodolfo V Guevara
NPI 1437368552
$1,214.90
in general payments reported to CMS, 2019-2025
17 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $115 · 2021: $65.40 · 2022: $102 · 2023: $299 · 2024: $129 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $187.92 | 2021-2025 | Breztri, Farxiga |
| Pfizer INC. | $145.45 | 2022-2025 | |
| Exact Sciences Corporation | $128.22 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $115.03 | 2020 | |
| Lilly USA, LLC | $99.55 | 2023-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.88 | 2023-2024 | Xifaxan |
| Novo Nordisk INC | $94.73 | 2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $54.81 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $52.93 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $45.34 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.06 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $38.76 | 2025 | Zoryve |
| Globus Medical, INC. | $34.64 | 2025 | Senza |
| Sunovion Pharmaceuticals INC. | $24.62 | 2022 | |
| Neurocrine Biosciences, INC. | $22.92 | 2023 | Ingrezza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17.33 | 2025 | Otezla, Repatha |
| Currax Pharmaceuticals LLC | $14.71 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodolfo Guevara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.